PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Real-time Estimate Cboe BZX  -  05/27 02:49:45 pm EDT
8.805 USD   +5.96%
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
CI
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
MT
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
7.83(c) 7.7(c) 7.86(c) 8.31(c) 8.8 Last
1 138 235 921 505 951 431 861 743 405 906 Volume
-1.14% -1.66% +2.08% +5.73% +5.90% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 31,9 M - -
Net income 2022 -157 M - -
Net cash position 2022 174 M - -
P/E ratio 2022 -2,63x
Yield 2022 -
Sales 2023 8,75 M - -
Net income 2023 -201 M - -
Net cash position 2023 151 M - -
P/E ratio 2023 -2,24x
Yield 2023 -
Capitalization 404 M 404 M -
EV / Sales 2022 7,22x
EV / Sales 2023 29,0x
Nbr of Employees 122
Free-Float 98,6%
More Financials
Company
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin... 
More about the company
Ratings of Protagonist Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROTAGONIST THERAPEUTICS, INC.
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results i..
CI
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reitera..
MT
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
05/05SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outpe..
MT
05/04PROTAGONIST THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/26Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bo..
MT
04/26Top Midday Decliners
MT
04/26Top Premarket Decliners
MT
04/26PROTAGONIST THERAPEUTICS : Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ul..
PU
04/26PROTAGONIST THERAPEUTICS, INC : Financial Statements and Exhibits (form 8-K)
AQ
04/25TRANSCRIPT : Protagonist Therapeutics, Inc. - Special Call
CI
04/25Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
PR
04/25Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
CI
04/19PROTAGONIST THERAPEUTICS : Initial Statement of Beneficial Ownership (Form 3)
PU
More news
News in other languages on PROTAGONIST THERAPEUTICS, INC.
05/26Protagonist Therapeutics, Inc. présentera les résultats cliniques actualisés de la phas..
05/04Protagonist Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 3..
04/26Les actions de Protagonist Therapeutics chutent après la publication des résultats d'un..
04/25Protagonist Therapeutics annonce les premières données de l'étude IDEAL de phase 2 sur ..
04/14MISE À JOUR SECTORIELLE : Les actions du secteur de la santé s'estompent en fin de journée..
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 8,31 $
Average target price 40,00 $
Spread / Average Target 381%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-75.70%404
MODERNA, INC.-46.53%54 016
LONZA GROUP AG-28.07%42 292
IQVIA HOLDINGS INC.-26.37%39 319
SEAGEN INC.-10.44%25 487
ICON PUBLIC LIMITED COMPANY-29.73%17 693